{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:46:42Z","timestamp":1790700402550,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.msard.2022.104168","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T03:51:48Z","timestamp":1662695508000},"page":"104168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The Prevalence, Demographics, Clinical Features, Neuroimaging, and Inter-ethnic Differences of MOGAD in Malaysia with Global Perspectives"],"prefix":"10.1016","volume":"67","author":[{"given":"ZM","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Arip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YM","family":"Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Terumalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SH","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Adenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104168_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2018.10.016","article-title":"Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein","volume":"130","author":"Akaishi","year":"2019","journal-title":"Neurochem Int"},{"issue":"6","key":"10.1016\/j.msard.2022.104168_bib0012","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neurol.2018.02.084","article-title":"Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes","volume":"174","author":"Alves Do Rego","year":"2018","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"10.1016\/j.msard.2022.104168_bib0004","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1471-4159.1989.tb10930.x","article-title":"Differential ultrastructural localization of myelin basic protein, myelin\/oligodendroglial glycoprotein, and 2\u2032,3\u2032-cyclic nucleotide 3\u2032-phosphodiesterase in the CNS of adult rats","volume":"52","author":"Brunner","year":"1989","journal-title":"J Neurochem"},{"issue":"10","key":"10.1016\/j.msard.2022.104168_bib0008","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/1352458510376406","article-title":"Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis","volume":"16","author":"Chan","year":"2010","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2022.104168_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.msard.2022.104168_bib0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.neurad.2019.06.001","article-title":"MRI features of demyelinating disease associated with anti-MOG antibodies in adults","volume":"46","author":"Deneve","year":"2019","journal-title":"J Neuroradiol"},{"issue":"3","key":"10.1016\/j.msard.2022.104168_bib0016","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA neurology"},{"issue":"Pt 8","key":"10.1016\/j.msard.2022.104168_bib0005","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/awl075","article-title":"Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research","volume":"129","author":"Gold","year":"2006","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2022.104168_bib0031","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment Approaches for MOG-Ab-Associated Demyelination in Children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"10.1016\/j.msard.2022.104168_bib0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"12","key":"10.1016\/j.msard.2022.104168_bib0014","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2022.104168_bib0028","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/WCO.0000000000000315","article-title":"Central nervous system neuroinflammatory disorders in Asian\/Pacific regions","volume":"29","author":"Kim","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"10.1016\/j.msard.2022.104168_bib0009","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2022.104168_bib0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2022.104168_bib0022","unstructured":"Malaysia DoS. Demographic Statistics First Quarter 2021, Malaysia Malaysia2021 [Available from: https:\/\/www.dosm.gov.my\/v1\/index.php?r=column\/cthemeByCat&cat=430&bul_id=aVlJRDAvbjhWWEhQa1YvSWhsSjF3QT09&menu_id=L0pheU43NWJwRWVSZklWdzQ4TlhUUT09."},{"key":"10.1016\/j.msard.2022.104168_bib0007","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.msard.2022.104168_bib0006","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nature medicine"},{"key":"10.1016\/j.msard.2022.104168_bib0030","article-title":"Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India","volume":"2","author":"Pandit","year":"2016","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"17","key":"10.1016\/j.msard.2022.104168_bib0003","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1073\/pnas.90.17.7990","article-title":"Myelin\/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex","volume":"90","author":"Pham-Dinh","year":"1993","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6","key":"10.1016\/j.msard.2022.104168_bib0002","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1046\/j.1471-4159.1994.63062353.x","article-title":"Characterization and expression of the cDNA coding for the human myelin\/oligodendrocyte glycoprotein","volume":"63","author":"Pham-Dinh","year":"1994","journal-title":"J Neurochem"},{"key":"10.1016\/j.msard.2022.104168_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti MOG antibodies are present in a subgroup of patients with neuromyelitis optica phenotype","volume":"12","author":"Probstel","year":"2015","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.msard.2022.104168_bib0001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.msard.2022.104168_bib0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"10.1016\/j.msard.2022.104168_bib0026","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","volume":"26","author":"Salama","year":"2020","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.msard.2022.104168_bib0029","first-page":"1381","article-title":"Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka","volume":"90","author":"Senanayake","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.msard.2022.104168_bib0027","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458515614093","article-title":"The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients","volume":"22","author":"Siritho","year":"2016","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.msard.2022.104168_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2022.104168_bib0024","article-title":"Multiple sclerosis in malaysia: demographics, clinical features, and neuroimaging characteristics","volume":"2013","author":"Viswanathan","year":"2013","journal-title":"Mult Scler Int"},{"key":"10.1016\/j.msard.2022.104168_bib0023","article-title":"The frequency of anti-aquaporin-4 Ig g antibody in neuromyelitis optica and its spectrum disorders at a single tertiary referral center in malaysia","volume":"2014","author":"Viswanathan","year":"2014","journal-title":"Mult Scler Int"},{"issue":"12","key":"10.1016\/j.msard.2022.104168_bib35","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: Results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2022.104168_bib0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.msard.2022.104168_bib0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:50Z","timestamp":1761901550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":32,"alternative-id":["S2211034822006745"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104168","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prevalence, Demographics, Clinical Features, Neuroimaging, and Inter-ethnic Differences of MOGAD in Malaysia with Global Perspectives","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104168"}}